

Ref. No: 2092
Date: 06/10/25
Subject: New Asthma Prescribing

REQUEST

How many new patients were treated for Asthma by the Trusts Respiratory Department in the latest 4 month period (April - July 2025) with the treatments I have provided below?

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st April 2024, they can be classed as a new patient for the purposes of this question.

- Cinquaero (Reslizumab)
- Dupixent (Dupilumab)
- Fasenra (Benralizumab)
- Nucala (Mepolizumab)
- Tezpire (Tezepelumab)
- Xolair (Omalizumab)

RESPONSE

- Cinquaero (Reslizumab) 0
- Dupixent (Dupilumab) 0
- Fasenra (Benralizumab) 0
- Nucala (Mepolizumab) 0
- Tezpire (Tezepelumab) 0
- Xolair (Omalizumab) 0